AbbVie wows with $30bn blockbuster
AbbVie enjoyed the undivided attention of US bond investors on Tuesday when it hit the market with a $30bn 10 tranche deal that, remarkably for such a big deal, priced with a negative new issue concession.
Proceeds will be used to help finance AbbVie’s $63bn acquisition of botox maker Allergan, which was given regulatory approval on October 25. (Picture shows AbbVie's CEO Richard Gonzalez)Investors poured $75bn of orders into the biggest high grade deal of the year, underlining the amount of money they ...
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: email@example.com